Goldman Sachs
VIRX

Goldman Sachs’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Goldman Sachs’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,090
Closed -$6.27K – 6331
2024
Q3 		$6.27K Buy
+27,090
New +$9.93K ﹤0.01% 5724
2022
Q4 		– Sell
-117,493
Closed -$502K – 6319
2022
Q3 		$502K Sell
117,493
-86,671
-42% -$367K ﹤0.01% 4965
2022
Q2 		$792K Buy
204,164
+53,475
+35% +$152K ﹤0.01% 4787
2022
Q1 		$717K Sell
150,689
-41,562
-22% -$125K ﹤0.01% 5090
2021
Q4 		$702K Buy
192,251
+21,057
+12% +$112K ﹤0.01% 5120
2021
Q3 		$1.37M Sell
171,194
-90,319
-35% -$890K ﹤0.01% 4504
2021
Q2 		$2.97M Sell
261,513
-342,461
-57% -$3.44M ﹤0.01% 3838
2021
Q1 		$5.59M Buy
603,974
+595,006
+6,635% +$6.2M ﹤0.01% 3033
2020
Q4 		$62K Buy
8,968
+5,502
+159% +$28.7K ﹤0.01% 5353
2020
Q3 		$15K Buy
3,466
+3,133
+941% +$27.4K ﹤0.01% 5257
2020
Q2 		$3K Buy
+333
New +$5.02K ﹤0.01% 5161
2018
Q2 		– Sell
-4,634
Closed -$441K – 6091
2018
Q1 		$441K Buy
+4,634
New +$795K ﹤0.01% 4561
2016
Q3 		– Sell
-252
Closed -$29K – 7224
2016
Q2 		$29K Buy
252
+1
+0.4% +$111 ﹤0.01% 6600
2016
Q1 		$28K Sell
251
-54
-18% -$8.19K ﹤0.01% 6644
2015
Q4 		$57K Sell
305
-263
-46% -$49.2K ﹤0.01% 6476
2015
Q3 		$97K Sell
568
-2,128
-79% -$768K ﹤0.01% 6502
2015
Q2 		$1.7M Buy
2,696
+2,083
+340% +$1.11M ﹤0.01% 4008
2015
Q1 		$315K Buy
613
+23
+4% +$11.6K ﹤0.01% 5595
2014
Q4 		$316K Buy
590
+113
+24% +$50.9K ﹤0.01% 5729
2014
Q3 		$715K Buy
477
+383
+407% +$554K ﹤0.01% 4952
2014
Q2 		$128K Sell
94
-251
-73% -$291K ﹤0.01% 6455
2014
Q1 		$479K Sell
345
-918
-73% -$1.07M ﹤0.01% 5318
2013
Q4 		$1.26M Buy
1,263
+1,157
+1,092% +$1.2M ﹤0.01% 4532
2013
Q3 		$111K Buy
106
+34
+47% +$36.3K ﹤0.01% 6128
2013
Q2 		$78K Buy
+72
New +$80.2K ﹤0.01% 5944

Other funds holding VIRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's VIRX Position: Q4 2024 in Review

Goldman Sachs sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2024, closing a stake of 27,090 shares — an estimated $6.27K sold.

Goldman Sachs first reported a position in VIRX in Q2 2013 and held it in 25 quarters. The position peaked at $5.59M in Q1 2021. 32 funds tracked by Wall St. Rank hold VIRX as of Q4 2024.

  • Goldman Sachs reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Goldman Sachs sold 27,090 Viracta Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $6.27K.
  • Goldman Sachs first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 25 quarters.
  • Goldman Sachs's Viracta Therapeutics, Inc. Common Stock position peaked at $5.59M in Q1 2021.
  • 32 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Goldman Sachs's 13F filing for Q4 2024, filed 11 Feb 2025.